Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.
García-Sanz R, Ocio E, Caballero A, Magalhães RJ, Alonso J, López-Anglada L, Villaescusa T, Puig N, Hernández JM, Fernández-Calvo J, Aguilar A, Martín A, López R, Paiva B, Orfao A, Vidriales B, San-Miguel JF, Del Carpio D.
García-Sanz R, et al. Among authors: vidriales b.
Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):168-71. doi: 10.3816/CLML.2011.n.040.
Clin Lymphoma Myeloma Leuk. 2011.
PMID: 21856552